AlzeCure Pharma (ALZCUR) Investor update summary

Strategic partnerships and business model

• Secured two transformative out-licensing and collaboration deals with Eli Lilly and QuantumCell, totaling over $3.2 billion in deal value, excluding royalties.

• Received $22 million in upfront payments and completed a SEK 30 million rights issue, strengthening the cash position.

• Awarded a €2.5 million grant from the European Innovation Council for the ACD856 phase IIa Alzheimer's trial.

• Business model centers on identifying CNS targets, developing small molecules in-house, and out-licensing after clinical development.

• Ongoing collaborations with Eli Lilly and QuantumCell involve active tech transfer, program initiation, and milestone funding.

Pipeline and therapeutic focus

• Focused on Alzheimer's and pain, addressing large unmet medical needs with multi-billion dollar market potential.

• Alzstatin platform (ACD680), a gamma-secretase modulator for Alzheimer's, out-licensed to Eli Lilly with global rights and deal value over $1 billion.

• NeuroRestore platform (ACD856), a Trk-PAM for cognitive disorders, out-licensed to QuantumCell for $2.2 billion in total deal value.

• Painless platform includes ACD137 (TrkA-NAM) for osteoarthritis and ACD440 (TRPV1 antagonist) for neuropathic pain and erythromelalgia.

• ACD440 has shown positive phase IIa results, significant pain reduction, and received orphan drug designation from FDA and EMA.

Clinical progress and scientific validation

• Alzstatin aims to reduce and clear amyloid plaques in the brain, with preclinical data supporting efficacy.

• NeuroRestore molecules enhance BDNF and NGF signaling, showing improved learning, memory, and disease-modifying effects in preclinical models.

• ACD137 offers a non-opioid mechanism for pain with potential for disease modification and oral administration.

• ACD440 demonstrated a 50% analgesic effect in neuropathic pain patients and is advancing toward pivotal trials.

• Multiple value drivers in the pipeline, including wholly owned pain assets and ongoing royalty streams from out-licensed programs.